研究の紹介:CKD-MBD

保存期CKD患者における血清Mg濃度と冠動脈石灰化密度の関係(解説

PLoS One. 11(9):e0163673, 2016. doi: 10.1371/journal.pone.0163673. PMID 27662624

Association between Density of Coronary Artery Calcification and Serum Magnesium Levels among Patients with Chronic Kidney Disease.

Sakaguchi Y, Hamano T, Nakano C, Obi Y, Matsui I, Kusunoki Y, Mori D, Oka T, Hashimoto N, Takabatake Y, Takahashi A, Kaimori JY, Moriyama T, Yamamoto R, Horio M, Sugimoto K, Yamamoto K, Rakugi H, Isaka Y.

腎尿細管間質障害に対する25-hydroxyvitamin D3の直接作用(解説

Kidney Int. 2015; 88(5): 1013-29. PMID 26176830

Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury by modulating the phenotype of macrophages in mice

Kusunoki Y, Matsui I, Hamano T, Shimomura A, Mori D, Yonemoto S, Takabatake Y, Tsubakihara Y, St-Arnaud R, Isaka Y, and Rakugi H.

マグネシウムは非糖尿病性慢性腎臓病患におけるリンと腎不全進行リスクの関連を修飾する(解説

Kidney Int. 2015; 88(4): 833-42. PMID 26061542

Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease

Sakaguchi Y, Iwatani H, Hamano T, Tomida K, Kawabata H, Kusunoki Y, Shimomura A, Matsui I, Hayashi T, Tsubakihara Y, Isaka Y, and Rakugi H.

L-リジンは血管石灰化を抑制する(解説

J Am Soc Nephrol 2014; 25: 1954-65, PMID 24652795

Dietary L-lysine prevents arterial calcification in adenine-induced uremic rats

Shimomura A, Matsui I, Hamano T, Ishimoto T, Katou Y, Takehana K, Inoue K, Kusunoki Y, Mori D, Nakano C, Obi Y, Fujii N, Takabatake Y, Nakano T, Tsubakihara Y, Isaka Y, Rakugi H.

ビタミンDの欠乏は 移植腎機能の低下を予測する(解説

J Clin Endocrinol Metab 2014; 99: 527-35, PMID 24285688

Vitamin D deficiency predicts decline in kidney allograft function: a prospective cohort study.

Obi Y, Hamano T, Ichimaru N, Tomida K, Matsui I, Fujii N, Okumi M, Kaimori JY, Yazawa K, Kokado Y, Nonomura N, Rakugi H, Takahara S, Isaka Y, Tsubakihara Y.

ステロイド骨粗鬆症におけるMDCTの有用性(解説

J Bone Miner Metab 2014; 32: 271-80, PMID 23832575

Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis.

Inoue K, Hamano T, Nango N, Matsui I, Tomida K, Mikami S, Fujii N, Nakano C, Obi Y, Shimomura A, Kusunoki Y, Rakugi H, Isaka Y, Tsubakihara Y.

異所性石灰化抑制因子fetuin-Aの腎臓における役割(解説

Am J Physiol Renal Physiol 2013; 304: F751-60, PMID 23344571

Retention of fetuin-A in renal tubular lumen protects the kidney from nephrocalcinosis in rats.

Matsui I, Hamano T, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Michigami T, Ohnishi T, Fujii N, Nakano C, Kusunoki Y, Kitamura H, Iwatani H, Takabatake Y, Kaimori JY, Matsuba G, Okoshi K, Kimura-Suda H, Tsubakihara Y, Rakugi H, Isaka Y.

活性型ビタミンD類似体による腎尿細管間質線維化抑制作用 (解説

Lab Invest 2012; 92: 1686-97, PMID 22926646

Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3.

Inoue K, Matsui I, Hamano T, Fujii N, Shimomura A, Nakano C, Kusunoki Y, Takabatake Y, Hirata M, Nishiyama A, Tsubakihara Y, Isaka Y, Rakugi H.

保存期慢性腎臓病(CKD)患者におけるFGF23と25(OH)D測定の併用は、腎予後のリスク評価に有用(解説

Clin J Am Soc Nephrol 2012; 7: 810-9, PMID 22362065

Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.

Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H.

保存期慢性腎臓病(CKD)患者のFGF23値は、透析導入前の心血管病発症を予測するが、透析導入後の心血管病発症までは予測しない(解説

Bone 2012; 50: 1266-74, PMID 22425694

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.

Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, Mikami S, Inoue K, Shimomura A, Nagasawa Y, Okada N, Tsubakihara Y, Rakugi H, Isaka Y.

慢性腎臓病患者さんにおける冠動脈石灰化とfetuin-mineral complex(解説

J Am Soc Nephrol 2010; 21: 1998-2007, PMID 20947626

Fetuin-mineral complex reflects extraosseous calcification stress in CKD.

Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, Isaka Y.

慢性腎臓病患者におけるビタミンD代謝異常と糖尿病(解説

Bone 2009; 45: 949-55, PMID 19631779

The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.

Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, Nagasawa Y, Ito T, Moriyama T, Horio M, Imai E, Isaka Y, Rakugi H.

非糖尿病慢性腎臓病患者における25-hydroxyvitamin D(解説

Bone 2009; 44: 678-83, PMID 19111635

Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.

Tomida K, Hamano T, Mikami S, Fujii N, Okada N, Matsui I, Nagasawa Y, Moriyama T, Ito T, Imai E, Isaka Y, Rakugi H.

糸球体上皮細胞傷害の修復とvitamin D(解説

Nephrol Dial Transplant 2009; 24: 2354-61, PMID 19297354

Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats.

Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, Kawada N, Ito T, Kawachi H, Rakugi H, Imai E, Isaka Y.

腎不全における異所性石灰化のメカニズム(解説

Kidney Int 2009; 75: 915-28, PMID 19190677

Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failure.

Matsui I, Hamano T, Mikami S, Fujii N, Takabatake Y, Nagasawa Y, Kawada N, Ito T, Rakugi H, Imai E, Isaka Y.